Zobrazeno 1 - 10
of 66
pro vyhledávání: '"Lukkana Suksanpaisan"'
Autor:
Kelly M. Makielski, Aaron L. Sarver, Michael S. Henson, Kathleen M. Stuebner, Antonella Borgatti, Lukkana Suksanpaisan, Caitlin Preusser, Alexandru-Flaviu Tabaran, Ingrid Cornax, M. Gerard O’Sullivan, Andrea Chehadeh, Donna Groschen, Kelly Bergsrud, Sara Pracht, Amber Winter, Lauren J. Mills, Marc D. Schwabenlander, Melissa Wolfe, Michael A. Farrar, Gary R. Cutter, Joseph S. Koopmeiners, Stephen J. Russell, Jaime F. Modiano, Shruthi Naik
Publikováno v:
Molecular Therapy: Oncolytics, Vol 31, Iss , Pp 100736- (2023)
Osteosarcoma is a devastating bone cancer that disproportionally afflicts children, adolescents, and young adults. Standard therapy includes surgical tumor resection combined with multiagent chemotherapy, but many patients still suffer from metastati
Externí odkaz:
https://doaj.org/article/f4f7cab98bbe4ae5a0cfe31df10cc42c
Autor:
Clara T. Nicolas, Robert A. Kaiser, Raymond D. Hickey, Kari L. Allen, Zeji Du, Caitlin J. VanLith, Rebekah M. Guthman, Bruce Amiot, Lukkana Suksanpaisan, Bing Han, Maria Giovanna Francipane, Amin Cheikhi, Huailei Jiang, Aditya Bansal, Mukesh K. Pandey, Ishan Garg, Val Lowe, Aditya Bhagwate, Daniel O’Brien, Jean-Pierre A. Kocher, Timothy R. DeGrado, Scott L. Nyberg, Eric Lagasse, Joseph B. Lillegard
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 18, Iss , Pp 738-750 (2020)
The effectiveness of cell-based therapies to treat liver failure is often limited by the diseased liver environment. Here, we provide preclinical proof of concept for hepatocyte transplantation into lymph nodes as a cure for liver failure in a large-
Externí odkaz:
https://doaj.org/article/8ffcb39c8aed4257acfa76228d16a408
Autor:
Lianwen Zhang, Lukkana Suksanpaisan, Huailei Jiang, Timothy R. DeGrado, Stephen J. Russell, Ming Zhao, Kah-Whye Peng
Publikováno v:
Molecular Therapy: Oncolytics, Vol 15, Iss , Pp 178-185 (2019)
Noninvasive dual-imaging methods that provide an early readout on tumor permissiveness to virus infection and tumor cell death could be valuable in optimizing development of oncolytic virotherapies. Here, we have used the sodium iodide symporter (NIS
Externí odkaz:
https://doaj.org/article/06b2d49822da43eba0a11a88afc2524f
Autor:
Rianna Vandergaast, Timothy Carey, Samantha Reiter, Chase Lathrum, Patrycja Lech, Clement Gnanadurai, Michelle Haselton, Jason Buehler, Riya Narjari, Luke Schnebeck, Anne Roesler, Kara Sevola, Lukkana Suksanpaisan, Alice Bexon, Shruthi Naik, Bethany Brunton, Scott C. Weaver, Grace Rafael, Sheryl Tran, Alina Baum, Christos A. Kyratsous, Kah Whye Peng, Stephen J. Russell
Publikováno v:
mSphere, Vol 6, Iss 3 (2021)
Since its emergence at the end of 2019, SARS-CoV-2, the causative agent of COVID-19, has caused over 100 million infections and 2.4 million deaths worldwide. Recently, countries have begun administering approved COVID-19 vaccines, which elicit strong
Externí odkaz:
https://doaj.org/article/fd6c7795e5dc4c6292e6a1ae0c6f3949
Autor:
Lukkana Suksanpaisan, Rong Xu, Mulu Z. Tesfay, Carolyn Bomidi, Stefan Hamm, Rianna Vandergaast, Nathan Jenks, Michael B. Steele, Ayuko Ota-Setlik, Hinna Akhtar, Amara Luckay, Rebecca Nowak, Kah Whye Peng, John H. Eldridge, David K. Clarke, Stephen J. Russell, Rosa Maria Diaz
Publikováno v:
Molecular Therapy: Oncolytics, Vol 10, Iss , Pp 1-13 (2018)
Immunotherapy for HPVPOS malignancies is attractive because well-defined, viral, non-self tumor antigens exist as targets. Several approaches to vaccinate therapeutically against HPV E6 and E7 antigens have been adopted, including viral platforms suc
Externí odkaz:
https://doaj.org/article/3396dace4a2548be8e2c17cb86f01e32
Autor:
Amber Miller, Lukkana Suksanpaisan, Shruthi Naik, Rebecca Nace, Mark Federspiel, Kah Whye Peng, Stephen J Russell
Publikováno v:
Molecular Therapy: Oncolytics, Vol 1, Iss C (2014)
Systemically administered oncolytic viruses have the ability to cause tumor destruction through the expansion and coalescence of intratumoral infectious centers. Efficacy is therefore dependent upon both the density and intratumoral distribution of v
Externí odkaz:
https://doaj.org/article/b056060eb1de4a149784c7300086e369
Autor:
Kent Bailey, Amber Kirk, Shruthi Naik, Rebecca Nace, Michael B Steele, Lukkana Suksanpaisan, Xing Li, Mark J Federspiel, Kah-Whye Peng, David Kirk, Stephen J Russell
Publikováno v:
PLoS ONE, Vol 8, Iss 9, p e73759 (2013)
Simple, inductive mathematical models of oncolytic virotherapy are needed to guide protocol design and improve treatment outcomes. Analysis of plasmacytomas regressing after a single intravenous dose of oncolytic vesicular stomatitis virus in myeloma
Externí odkaz:
https://doaj.org/article/8c76d8540814499081db66081136914d
Autor:
Kelly M. Makielski, Aaron L. Sarver, Michael S. Henson, Kathleen M. Stuebner, Antonella Borgatti, Lukkana Suksanpaisan, Caitlin Preusser, Alexandru-Flaviu Tabaran, Ingrid Cornax, M. Gerard O’Sullivan, Andrea Chehadeh, Donna Groschen, Kelly Bergsrud, Sara Pracht, Amber Winter, Lauren J. Mills, Marc D. Schwabenlander, Melissa Wolfe, Michael A. Farrar, Gary R. Cutter, Joseph S. Koopmeiners, Stephen J. Russell, Jaime F. Modiano, Shruthi Naik
Publikováno v:
bioRxiv
VSV-IFNβ-NIS is a recombinant oncolytic vesicular stomatitis virus (VSV) that is being evaluated clinically for the treatment of advanced malignancies. As with other cancer immunotherapies, identifying biomarkers of response will be critical to the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::13c7479aafb74daf0df9b4d7bd0ee63e
https://europepmc.org/articles/PMC10153185/
https://europepmc.org/articles/PMC10153185/
Autor:
Saad S. Kenderian, Stephen J. Russell, Kah-Whye Peng, Neil E. Kay, Lukkana Suksanpaisan, Timothy R. DeGrado, Mukesh K. Pandey, Sameer A. Parikh, Michael W. Ruff, Paulina Horvei, Lionel Aurelien Kankeu Fonkoua, Evandro D. Bezerra, Mohamad M. Adada, Wendy K. Nevala, Erin E. Tapper, Ismail Can, Kendall J. Schick, Claudia Manriquez Roman, Michelle J. Cox, Michael J. Hansen, Alysha N. Newsom, Roman H. Khadka, Nan Yang, Mehrdad Hefazi, Elizabeth L. Siegler, Aditya Bansal, Reona Sakemura
Although chimeric antigen receptor T (CART)–cell therapy has been successful in treating certain hematologic malignancies, wider adoption of CART-cell therapy is limited because of minimal activity in solid tumors and development of life-threatenin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c51d0f2acd4e4df0522e71306ec4c315
https://doi.org/10.1158/2326-6066.c.6550503.v1
https://doi.org/10.1158/2326-6066.c.6550503.v1
Autor:
Saad S. Kenderian, Stephen J. Russell, Kah-Whye Peng, Neil E. Kay, Lukkana Suksanpaisan, Timothy R. DeGrado, Mukesh K. Pandey, Sameer A. Parikh, Michael W. Ruff, Paulina Horvei, Lionel Aurelien Kankeu Fonkoua, Evandro D. Bezerra, Mohamad M. Adada, Wendy K. Nevala, Erin E. Tapper, Ismail Can, Kendall J. Schick, Claudia Manriquez Roman, Michelle J. Cox, Michael J. Hansen, Alysha N. Newsom, Roman H. Khadka, Nan Yang, Mehrdad Hefazi, Elizabeth L. Siegler, Aditya Bansal, Reona Sakemura
Supplementary Table S1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00d1aa974e8da04139876ff3f9e4dfbc
https://doi.org/10.1158/2326-6066.22544007
https://doi.org/10.1158/2326-6066.22544007